Search

Displaying results 2071 - 2080 of 10000 in total
  1. Drug

    Saquinavir

    go.drugbank.com/drugs/DB01232
    ApprovedInvestigational

    In 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due to a relatively benign adverse effect profile as compared … [A214382] While its efficacy was initially limited by exceptionally poor oral bioavailability (approximately 4%),[L3450] its current indications require the co-administration of ritonavir - a potent enzyme

  2. Drug

    Vedolizumab

    go.drugbank.com/drugs/DB09033
    ApprovedInvestigational

    [L48216] Vedolizumab was developed by Takeda and approved by the FDA under the brand name ENTYVIO for the maintenance therapy of moderately to severely active Ulcerative Colitis and Crohn’s Disease … [A261576] Vedolizumab is administered by IV infusion over a period of 30 minutes; after the first dose, it is given again at two and six weeks and then every 8 weeks thereafter.

  3. Drug

    Ceftaroline fosamil

    go.drugbank.com/drugs/DB06590
    ApprovedInvestigational

    Ceftaroline fosamil is a cephalosporin antibacterial indicated for the treatment of the following infections caused by designated susceptible bacteria: Acute bacterial skin and skin structure infections

    Synonyms: (6R,7R)-7-[(2Z)-2-ethoxyimino-2-[5-(phosphonoamino)-1,2,4-thiadiazol-3-yl]acetyl]amino]-3-[4-(1-methylpyridin-1-ium-4-yl)-1,3-thiazol-2-yl]sulfanyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
  4. Drug

    Patent Blue

    go.drugbank.com/drugs/DB13967
    ApprovedInvestigational

    Patent blue was developed by Guerbet and approved by Health Canada on December 31, 1979.[L1113] The isomer isosulphan is used in the United States for the same indications than patent blue.[A32574]

  5. Drug

    Sparfloxacin

    go.drugbank.com/drugs/DB01208
    ApprovedWithdrawn

    Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase.

  6. Drug

    Ragweed pollen extract

    go.drugbank.com/drugs/DB05368
    ApprovedWithdrawn

    Ragweed pollen extract has been developed by Curalogic. The company has initiated a phase III trial with its product for oral immunotherapy of ragweed allergy. … While traditional disease-modifying immunotherapeutics are administered by subcutaneous injection, Curalogic has developed a more convenient orally administered drug.

  7. Drug

    Nonivamide

    go.drugbank.com/drugs/DB11324
    Approved

    It is naturally found in chili peppers but manufactured to produce a synthetic form for various pharmacologic preparations [L2641].

    Mixtures: NEW AMMELTZ YOKO YOKO, NEW AMMELTZ YOKO YOKO GOLD TOPICAL LIQUIDSynonyms: N-Vanillylnonamide, N-Nonanoyl vanillylamide
  8. Drug

    Brompheniramine

    go.drugbank.com/drugs/DB00835
    Approved

    Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria.

    Synonyms: 3-(p-bromophenyl)-3-(2-pyridyl)-N,N-dimethylpropylamine, 3-(4-bromophenyl)-N,N-dimethyl-3-(2-pyridinyl)-1-propanamineMixtures: Atuss Da, Atuss Da
  9. Drug

    Capivasertib

    go.drugbank.com/drugs/DB12218
    ApprovedInvestigational

    Although endocrine-based therapy is the first line of treatment, resistance eventually emerges, leaving chemotherapy the only but often ineffective treatment left. … [A262021,A262026,A262031] On November 17th, 2023, capivasertib, under the brand name TRUQAP, was approved by the FDA for the treatment of adult patients HR-positive, HER2-negative locally advanced or

  10. Drug

    Indian frankincense

    go.drugbank.com/drugs/DB14275
    ApprovedInvestigational

    Indian frankincense is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.